Zobrazeno 1 - 10
of 190
pro vyhledávání: ''
Autor:
Hong Luo, Aiping Zhou, Jun Guo, Zhihong Chi, Chuanliang Cui, Xinan Sheng, Guohua Yu, Xin Yao, Xieqiao Yan, Benkang Shi, Lu Si, Lin Wang, Yun Ling, Weiqing Han, Ji-Yan Liu, Jianming Ying, Jianmin Fang, Changlu Hu, Zhisong He, Yanxia Shi
Publikováno v:
Clinical Cancer Research. 27:43-51
Purpose: To evaluate the efficacy and safety of RC48-ADC, a novel humanized anti-HER2 antibody conjugated with monomethyl auristatin E, in patients with HER2+ locally advanced or metastatic urothelial carcinoma (mUC) refractory to standard therapies.
Autor:
Kunle Odunsi, Ronald D. Alvarez, Wiam Bshara, Premal H. Thaker, Nicholas Borys, William H. Bradley, Charles A. Leath, Khursheed Anwer, Lauren Musso, Camille Gunderson Jackson, Junko Matsuzaki
Publikováno v:
Clin Cancer Res
Purpose: GEN-1 (phIL-12-005/PPC), an IL12 plasmid formulated with polyethyleneglycol-polyethyleneimine cholesterol lipopolymer, has preclinical activity when combined with platinum-taxane intravenous chemotherapy and administered intraperitoneally in
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b1c5a200a6081b685a254e029db9e889
https://europepmc.org/articles/PMC9338778/
https://europepmc.org/articles/PMC9338778/
Autor:
Judith V.M.G. Bovée, Sandrine Marreaud, Hans Gelderblom, Sophie Cousin, Céline Charon-Barra, Vasilios Karavasilis, Mehdi Brahmi, Patrick Schöffski, Laura De Meulemeester, Marta Domenech, Neeltje Steeghs, Maud Toulmonde, Monika Dudzisz-Śledź, Anna Estival, Saskia Litière, Gloria Marquina, Christine Olungu, Jacco J de Haan, Agnieszka Wozniak
Publikováno v:
European Journal of Cancer, 152, 26-40. ELSEVIER SCI LTD
European Journal of Cancer
r-IGTP. Repositorio Institucional de Producción Científica del Instituto de Investigación Germans Trias i Pujol
instname
European Journal of Cancer
r-IGTP. Repositorio Institucional de Producción Científica del Instituto de Investigación Germans Trias i Pujol
instname
PURPOSE: EORTC-1506-STBSG was a prospective, multicentric, randomised, open-label phase 2 trial to assess the efficacy and safety of second-line nintedanib versus ifosfamide in patients with advanced, inoperable metastatic soft tissue sarcoma (STS).
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::9ec0b634f0a2ff943778eb64e85e92f9
http://www.ejcancer.com/article/S095980492100246X/pdf
http://www.ejcancer.com/article/S095980492100246X/pdf
Publikováno v:
Cancer Reports, Vol 5, Iss 2, Pp n/a-n/a (2022)
Background Nivolumab has shown promising results against non‐small‐cell lung cancer (NSCLC). However, its efficacy to treat central nervous system (CNS) metastases, specifically among programmed cell death 1 ligand 1 (PD‐L1)‐negative patients
Autor:
Suzanne F. Jones, Howard A. Burris, Joseph Stilwill, Dianna Shipley, Cindy Jacobs, John D. Hainsworth, David R. Spigel, Brian Hemphill, Kent C. Shih, Patrick J. Ward, Ray D. Page, Tarek Mekhail, Michael McCleod, Robert C. Whorf, David M. Waterhouse
Publikováno v:
The Oncologist. 24:e1409-e1416
Background This randomized, double-blinded, phase II trial evaluated the efficacy of carboplatin and pemetrexed plus either apatorsen, an antisense oligonucleotide targeting heat shock protein (Hsp) 27 mRNA, or placebo in patients with previously unt
Autor:
Shah-Jalal Sarker, Katherine Mutsvangwa, Anand Sharma, Naveed Sarwar, Rizwan Syed, Jonathan Shamash, Gordon J. S. Rustin, Peter Wilson, Carike Coetzee
Publikováno v:
European Journal of Cancer. 115:128-135
Introduction Carboplatin monotherapy for metastatic seminoma at a dose of AUC-10 has shown promising activity. Three or four cycles have been given with most haematological side-effects seen with the 4th cycle. An early response might allow de-escala
Publikováno v:
Oncology Research
Apatinib is an oral TKI with antiangiogenic properties, and it is currently approved for the treatment of advanced gastric cancer in China. This agent has also been tested in other human solid tumors, including non-small cell lung cancer (NSCLC). Sin
Autor:
Kenji Tamura, Hiroki Ikezawa, Toshio Shimizu, Kan Yonemori, Takafumi Koyama, Noboru Yamamoto, Maiko Nomoto, Keiji Furuuchi, Ryo Nakajima, Akihiko Shimomura, Jun Sato, Yutaka Fujiwara, Takuma Miura
Publikováno v:
Clinical cancer research : an official journal of the American Association for Cancer Research. 27(14)
Purpose: MORAb-202, an antibody–drug conjugate containing farletuzumab and eribulin with a cathepsin-B cleavable linker, targets folate receptor α (FRα)–expressing tumor cells. The primary objective of this first-in-human study was to evaluate
Autor:
Suayib Yalcin, Sahin Lacin
Publikováno v:
Technology in Cancer Research & Treatment
Technology in Cancer Research & Treatment, Vol 19 (2020)
Technology in Cancer Research & Treatment, Vol 19 (2020)
Background: Neovascularization plays a crucial pathogenic role in tumor development and vascular endothelial growth factor (VEGF-A) is a key signaling element that drives angiogenesis, thereby facilitating hepatocellular cancer (HCC) growth and metas
Autor:
Somvilai Chakrabandhu, Kittisak Chomprasert, Patrinee Traisathit, Wimrak Onchan, Tharatorn Tungkasamit, Tussawan Asakit, Rungarun Kittichest, Imjai Chitapanarux
Publikováno v:
Current problems in cancer. 45(1)
Background According to the noninferiority result of chemoradiation with carboplatin in our previous nasopharyngeal carcinoma (NPC) study along with the inconclusive data on the efficacy of adjuvant chemotherapy (AC) following concurrent chemoradioth